Journal
EUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume 26, Issue 9, Pages 666-669Publisher
ELSEVIER
DOI: 10.1016/j.ejim.2015.08.012
Keywords
Statins; Alzheimer's disease; Dementia; Disease prevention
Categories
Ask authors/readers for more resources
Alzheimer's disease is the most common cause of dementia and occurs commonly in patients 65 and older. There is an urgent need to find an effective management that could help prevent or at least slow down the progress of this major public health problem. Cholesterol related pathways might play a role in the pathogenesis of Alzheimer's disease. Treatment with 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) has been suggested to promote the prevention of Alzheimer's disease. In this review, we discuss potential pathogenetic pathways for the development of Alzheimer's disease and review the evidence regarding the value of statins as a strategy to prevent or delay progression of Alzheimer's disease. (C) 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available